Volitionrx Ltd 8-K, filed Dec 11, 2025
Volitionrx Ltd (VNRX)
About this 8-K
Volitionrx Ltd filed this 8-K on December 11, 2025, reporting on events of December 5, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of Incorporation) |
| File Number) |
| Identification Number) |
(Address of principal executive offices and zip code)
+1 (
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed from last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbol(s) |
| Name of Each Exchange on which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 5, 2025, Volition Veterinary Diagnostics Development, LLC (“Volition Veterinary”), a majority-owned subsidiary of VolitionRx Limited (the “Company”), provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026 (the “Termination Date”). The decision to end Dr. Butera’s employment was made for operational reasons and not as a result of any disagreement or dispute with the Company on any matter relating to the Company’s operations, policies or practices.
Effective January 31, 2026, Volition Veterinary will eliminate the Chief Executive Officer position as part of the Company’s ongoing cost-realignment efforts. Dr. Butera’s duties will be redistributed within the Company.
Following the Termination Date, it is intended that Dr. Butera will remain with Volition Veterinary on a part-time consulting basis, providing advisory services, subject to mutually agreed upon terms.
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VOLITIONRX LIMITED |
| |
|
|
| |
Date: December 11, 2025 | By: | /s/ Cameron Reynolds |
|
|
| Cameron Reynolds |
|
|
| Chief Executive Officer & President |
|
3 |